Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumour with metastatic propensity. Stereotactic body radiation therapy (SBRT) is an emerging therapeutic option for SCLC, despite limited supporting evidence. By evaluating the use of SBRT in very limited stage (VLS) SCLC at our institution, we aimed to contribute to the existing knowledge in this area while establishing a basis for further research. We performed a retrospective review of all cases of VLS-SCLC treated with SBRT between 2013 and 2020. Baseline demographics, diagnostic, and treatment information were collected. The primary outcome was overall survival (OS). We identified 46 patients with pathologically confirmed VLS-SCLC; 25 were treated with SBRT, and the remainder received either surgery, conventional radiation therapy, chemotherapy, or palliative-intent therapy. After a median follow-up of 23.7 months, 44% of the patients had died; the median OS was of 24.4 months for the SBRT cohort and 67.0 months for the curative intent non-SBRT cohort. The difference in disease recurrence and survival between cohorts was underpowered and not statistically significant. Higher baseline ECOG and comorbidity was noted in the SBRT cohort.

The Eastern Canadian Gastrointestinal Cancer Consensus Conference convened annually and was held in Fredericton, New Brunswick, from 18 to 20 September 2025. Attendees included experts in medical oncology, radiation oncology, nuclear medicine, and general practitioners in oncology (GPO) from across the eastern Canadian provinces who are engaged in the care and management of patients with gastrointestinal malignancies. The consensus statement resulting from this meeting addresses several key topics, including the management of early-stage gastroesophageal junction cancer, recent developments in molecular biomarkers and colorectal cancer treatments, secondary prevention strategies for colorectal cancer, and treatment of hepatocellular carcinoma.